The most frequently used mpox vaccine provides partial immunity to the disease but isn’t always able to prevent severe symptoms or disease transmission. A new vaccine candidate from Moderna, mRNA-1769, more effectively limits symptoms and disease duration in primates that were infected with a lethal strain of the mpox virus when compared to a currently licensed modified vaccinia Ankara (MVA) vaccine.